AmerisourceBergen resumed with an Outperform at Evercore ISI

Evercore ISI analyst Elizabeth Anderson resumed coverage of AmerisourceBergen with an Outperform rating and $185 price target. The company’s core drug distribution business and "formidable" specialty operations should generate mid-to-high single digit operating profit growth and double digit EPS growth over the medium-term, the firm tells investors. Evercore sees upside to valuation as visibility improves post-COVID, the firm added.